Table 2.

Guideline adherence in certified and non-certified centers

	Indication	Standard met in certified centers (%)	Standard met in non-certified centers (%)	p value	Odds ratio	95% confidence interval
High FN risk	Both indications	80.3	72.4	0.005	1.55	1.19–2.03
	Lung cancer	53.0	44.9	0.296	1.38	0.85–2.26
	Breast cancer	85.4	84.7	0.869	1.06	0.74–1.52
Intermediate FN risk	Both indications	53.8	46.2	0.033	1.24	1.05–1.42
	Lung cancer	45.1	43.8	0.750	1.06	0.85–1.31
	Breast cancer	60.2	55.0	0.139	1.24	1.00–1.53
Guideline adherence and specialties of the centers
	Indication	Standard met in organ-specific(pulmonological/gynecological) departments (%)	Standard met in hematological/oncological departments (%)	p value	Odds ratio	95% confidence interval
High FN risk	Lung cancer	25.0	43.6	< 0.001	0.26	0.14–0.46
	Breast cancer	86.2	82.5	0.288	1.37	0.90–1.93
Intermediate FN risk	Lung cancer	38.1	48.6	< 0.001	0.58	0.47–0.72
	Breast cancer	58.6	55.6	0.424	1.13	0.89–1.43
	Indication	Standard met in hospitals (%)	Standard met in office-based physicians (%)	p value	Odds ratio	95% confidence interval
High FN risk	Both indications	75.4	78.0	0.277	0.86	0.66–1.13
	Lung cancer	44.2	53.0	0.288	0.70	0.43–1.13
	Breast cancer	86.0	84.2	0.288	1.15	0.80–1.65
Intermediate FN risk	Both indications	47.6	57.1	< 0.001	0.68	0.59–0.80
	Lung cancer	40.1	56.3	< 0.001	0.52	0.41–0.67
	Breast cancer	58.0	57.5	0.869	1.02	0.83–1.27
Comparison of guideline adherence between the first cycle and subsequent cycles
	Indication	Standard met in first cycle (%)	Standard met in subsequent cycles (%)	p value	Odds ratio	95% confidence interval
High FN risk	Both indications	74.4	77.8	0.298	0.30	0.91–1.58
	Lung cancer	47.0	48.3	0.869	1.05	0.65–1.72
	Breast cancer	83.0	86.2	0.298	1.28	0.88–1.85
Intermediate FN risk	Both indications	51.3	51.1	0.948	0.99	0.85–1.16
	Lung cancer	41.0	46.1	0.168	1.13	0.98–1.55
	Breast cancer	61.3	55.9	0.139	0.80	0.64–1.00